Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | IGF1R | P08069 | 2/20 | 0.68 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.53 |
| ▸ | DRD1 | P21728 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13784937 | 0.90 | OPRM1 (0.63) | MEN1KMT2AOPRD1OPRM1OPRK1 | |
| SCHEMBL16757314 | 0.86 | SLC6A9 (0.55) | MEN1KMT2AIGF1ROPRM1OPRK1 | |
| SCHEMBL13856459 | 0.84 | KCNH2 (0.69) | MEN1KMT2AOPRM1OPRK1CHRM2 | |
| SCHEMBL16769328 | 0.84 | KCNH2 (0.69) | MEN1KMT2AOPRM1OPRK1CHRM2 | |
| SCHEMBL16769449 | 0.84 | KCNH2 (0.69) | MEN1KMT2AOPRM1OPRK1CHRM2 | |
| SCHEMBL4145335 | 0.81 | SLC6A9 (0.68) | MEN1KMT2AIGF1ROPRD1OPRM1 | |
| SCHEMBL4139140 | 0.81 | SLC6A9 (0.68) | MEN1KMT2AIGF1ROPRD1OPRM1 | |
| SCHEMBL4139144 | 0.81 | SLC6A9 (0.68) | MEN1KMT2AIGF1ROPRD1OPRM1 | |
| Hydrochloric Acid SCHEMBL4145669 | 0.80 | SLC6A9 (0.66) | MEN1KMT2AIGF1ROPRD1OPRM1 | |
| Hydrochloric Acid SCHEMBL4145673 | 0.80 | SLC6A9 (0.66) | MEN1KMT2AIGF1ROPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| WO-2015080949-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | NCOR1, RRP15, NCOA1 | MEN1 3157/4885KMT2A 1974/4885IGF1R 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.